Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Not Confirmed
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
27-30 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Industry Trade Show
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
27-30 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
04 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/04/3055929/33485/en/Xenon-to-Showcase-Long-Term-36-Month-Azetukalner-Data-at-AAN-2025.html
27 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/27/3034269/33485/en/Xenon-Reports-Fourth-Quarter-Full-Year-2024-Financial-Results-and-Business-Update.html
25 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/25/3032404/33485/en/Xenon-to-Present-at-the-45th-Annual-TD-Cowen-Healthcare-Conference.html
20 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/20/3030060/33485/en/Xenon-to-Report-Q4-and-Full-Year-2024-Financial-Results-on-February-27-2025.html
13 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/13/3008537/33485/en/Xenon-Outlines-Key-Corporate-Milestone-Opportunities-for-2025.html
07 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/07/3005429/33485/en/Xenon-to-Present-at-the-43rd-Annual-J-P-Morgan-Healthcare-Conference.html
Details:
The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Brand Name: XEN1101
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: J.P. Morgan
Deal Size: $225.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 29, 2023
Xenon Pharmaceuticals Announces Proposed Public Offering
Details : The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Product Name : XEN1101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 29, 2023
Details:
The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Brand Name: XEN1101
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: J.P. Morgan
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 29, 2023
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
Details : The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Product Name : XEN1101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 29, 2023
Details:
XEN1101 is a differentiated Kv7 potassium channel opener which is being evaluated under phase 2 clinical trials for the treatment of major depressive disorder (MDD).
Lead Product(s): XEN1101
Therapeutic Area: Psychiatry/Psychology Brand Name: XEN1101
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 27, 2023
Lead Product(s) : XEN1101
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XEN1101 is a differentiated Kv7 potassium channel opener which is being evaluated under phase 2 clinical trials for the treatment of major depressive disorder (MDD).
Product Name : XEN1101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 27, 2023
Details:
The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Brand Name: XEN1101
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: J.P. Morgan
Deal Size: $345.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 12, 2023
Details : The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Product Name : XEN1101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 12, 2023
Details:
Xenon has an ongoing collaboration with Neurocrine Biosciences to develop treatments for epilepsy. Neurocrine Biosciences has an exclusive license to XEN901, now known as NBI-921352, a selective Nav1.6 sodium channel inhibitor.
Lead Product(s): NBI-921352
Therapeutic Area: Neurology Brand Name: NBI-921352
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Neurocrine Biosciences
Deal Size: $1,775.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration December 01, 2022
Lead Product(s) : NBI-921352
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Neurocrine Biosciences
Deal Size : $1,775.0 million
Deal Type : Collaboration
Details : Xenon has an ongoing collaboration with Neurocrine Biosciences to develop treatments for epilepsy. Neurocrine Biosciences has an exclusive license to XEN901, now known as NBI-921352, a selective Nav1.6 sodium channel inhibitor.
Product Name : NBI-921352
Product Type : Other Small Molecule
Upfront Cash : $50.0 million
December 01, 2022
Details:
New XEN1101 Phase 2b X-TOLE sub-group analysis demonstrates statistically significant efficacy results at all doses at Week 1, differentiating XEN1101 with rapid onset to seizure reduction.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Brand Name: XEN1101
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 22, 2022
Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program
Details : New XEN1101 Phase 2b X-TOLE sub-group analysis demonstrates statistically significant efficacy results at all doses at Week 1, differentiating XEN1101 with rapid onset to seizure reduction.
Product Name : XEN1101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2022
Details:
The primary efficacy endpoint is the median percent change (MPC) in monthly seizure frequency from baseline through the DBP of XEN1101 compared to placebo.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Brand Name: XEN1101
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 21, 2022
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA
Details : The primary efficacy endpoint is the median percent change (MPC) in monthly seizure frequency from baseline through the DBP of XEN1101 compared to placebo.
Product Name : XEN1101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2022
Details:
XEN1101 is a differentiated Kv7 potassium channel opener administered as an adjunctive treatment for adult patients with focal epilepsy,being developed for the treatment of epilepsy and major depressive disorder.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Brand Name: XEN1101
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 11, 2022
Details : XEN1101 is a differentiated Kv7 potassium channel opener administered as an adjunctive treatment for adult patients with focal epilepsy,being developed for the treatment of epilepsy and major depressive disorder.
Product Name : XEN1101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2022
Details:
XEN1101, a KCNQ channel opener, has been studied in Phase 2b clinical trial in adult patients demonstrated compelling efficacy results, with a statistically significant and dose-dependent reduction from baseline in monthly focal seizure frequency when compared to placebo.
Lead Product(s): XEN1101
Therapeutic Area: Psychiatry/Psychology Brand Name: XEN1101
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 05, 2022
Lead Product(s) : XEN1101
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XEN1101, a KCNQ channel opener, has been studied in Phase 2b clinical trial in adult patients demonstrated compelling efficacy results, with a statistically significant and dose-dependent reduction from baseline in monthly focal seizure frequency when co...
Product Name : XEN1101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2022
Details:
XEN496, a Kv7 potassium channel modulator that is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE).
Lead Product(s): Ezogabine
Therapeutic Area: Neurology Brand Name: XEN496
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Jefferies
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 03, 2021
Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering
Details : XEN496, a Kv7 potassium channel modulator that is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE).
Product Name : XEN496
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 03, 2021
ABOUT THIS PAGE